Medline Director Joseph Baratta Will Resign From Board At Year-End After Leaving Blackstone
An 8-K says the resignation takes effect December 31, 2026, and is not the result of any disagreement with the company.
Medline director Joseph P. Baratta told the board on Tuesday that he will resign, effective December 31, 2026, according to an 8-K the company filed Thursday. The filing ties the decision to his previously announced departure from Blackstone.
What the 8-K says
The filing, made under Item 5.02 (the section covering director departures), says Baratta notified the board of Medline on October 13, 2026. His decision "coincides with his previously announced departure from Blackstone Inc."
Medline said the move is not the result of any disagreement with the company related to its operations, policies or practices. The board said it is grateful for his service and contributions.
Chief Legal Officer Alex M. Liberman signed the filing.
What it changes
Baratta stays on the board through the end of the year, so the seat is not vacant yet. The filing does not name a replacement.
Medline's Class A common stock trades on Nasdaq under MDLN. Shares closed at $36.57 at Thursday's close, up about 2% on the session, before the filing was accepted at 4:18 p.m. ET.
The resignation date is December 31, 2026, the next fixed point in the filing.
Sources
- 8-K Filing — Medline Inc. (MDLN) — SEC EDGAR